Comprehensive medication guide to Hyrimoz including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
With commercial insurance and the Sandoz One Source Co-Pay Program, out-of-pocket cost may be as low as $0 per dose. Without the copay program, specialty tier copays typically range from $50–$300+ per month. Medicare patients are not eligible for the manufacturer copay program and are subject to their Part D plan's specialty tier cost-sharing.
Estimated Cash Pricing
Branded Hyrimoz lists at approximately $3,500–$6,500 per month at retail; the Cordavis private-label (unbranded) version runs approximately $1,300–$1,900 per month — the lowest list price adalimumab option. GoodRx coupons bring some presentations to approximately $1,319.
Medfinder Findability Score
62/100
Summarize with AI
On this page
Hyrimoz (adalimumab-adaz) is an FDA-approved biologic medication and biosimilar to Humira (adalimumab), the world's best-selling drug. Manufactured by Sandoz Inc. (a Novartis company), Hyrimoz launched in the United States on July 1, 2023, following FDA approval in October 2018 for the original formulation and March 2023 for the high-concentration citrate-free version.
Hyrimoz is approved for nine inflammatory and autoimmune conditions: rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA, age 2+), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn's disease (adults and children 6+), ulcerative colitis (adults), plaque psoriasis (adults), hidradenitis suppurativa (adults), and uveitis (adults and children 2+).
Hyrimoz has FDA interchangeable designation — meaning pharmacists may substitute it for Humira or other interchangeable adalimumab biosimilars without a new prescription in most states. It has accumulated nearly 120 million patient-days of experience globally prior to its U.S. launch and is one of the most widely-used adalimumab biosimilars in the country, including through CVS Caremark's preferred formularies.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Hyrimoz is a fully human monoclonal antibody that targets and neutralizes tumor necrosis factor alpha (TNF-alpha), a protein produced by immune cells that plays a central role in driving inflammation. In autoimmune diseases like RA, Crohn's disease, and psoriasis, TNF-alpha is overproduced, causing chronic inflammation, tissue damage, and disease symptoms.
Hyrimoz works by binding to both soluble (free-circulating) and membrane-bound (cell surface) forms of TNF-alpha. By blocking TNF-alpha from attaching to its receptors on cells, Hyrimoz interrupts the inflammatory signaling cascade — reducing joint inflammation, gut inflammation, skin plaques, and other disease manifestations. Hyrimoz can also trigger cell death in certain TNF-producing immune cells through complement-dependent and antibody-dependent cytotoxicity mechanisms.
Because TNF-alpha normally helps fight infections, blocking it also reduces the immune system's ability to respond to bacteria, viruses, and fungi. This is why Hyrimoz carries a boxed warning for serious infections including tuberculosis, bacterial sepsis, and invasive fungal infections. Most patients see measurable improvement within 2–4 weeks, with maximum benefit typically by 12–24 weeks.
10 mg/0.1 mL — prefilled syringe (high-concentration, citrate-free)
Pediatric dosing for JIA and uveitis
20 mg/0.2 mL — prefilled syringe (high-concentration, citrate-free)
Pediatric dosing for JIA and uveitis
40 mg/0.4 mL — Sensoready Pen autoinjector and prefilled syringe (high-concentration, citrate-free)
Standard adult maintenance dose for RA, PsA, AS, and other conditions
80 mg/0.8 mL — Sensoready Pen autoinjector and prefilled syringe (high-concentration, citrate-free)
Loading/induction dose for Crohn's, UC, and plaque psoriasis
Hyrimoz is not on any official FDA or ASHP drug shortage list as of 2026. Sandoz continues to manufacture and distribute adalimumab-adaz in the United States. However, patient access to Hyrimoz can be inconsistent due to the complex specialty pharmacy and formulary landscape surrounding adalimumab biosimilars.
The most common barriers to finding Hyrimoz are: specialty pharmacy requirements (most retail pharmacies don't stock it), insurance formulary restrictions (different PBMs prefer different biosimilars), prior authorization delays, and the January 2026 discontinuation of some low-concentration formulations by Sandoz. CVS Specialty is generally the most reliable source, as CVS Caremark made Hyrimoz its preferred adalimumab biosimilar in April 2024. Express Scripts and Optum Rx patients may face higher hurdles, as those PBMs prefer competing biosimilars.
If you're having trouble locating Hyrimoz at a pharmacy near you, medfinder calls pharmacies in your area to find which ones have your medication in stock — so you don't have to make dozens of calls yourself.
Hyrimoz (adalimumab-adaz) is not a controlled substance and can be prescribed by any licensed physician (MD or DO), nurse practitioner (NP), or physician assistant (PA). However, because biologic therapies require baseline TB and HBV testing, ongoing monitoring, and complex prior authorization documentation, prescribing is primarily handled by specialists experienced with biologic DMARDs.
Rheumatologists — for RA, PsA, JIA, and ankylosing spondylitis
Gastroenterologists — for Crohn's disease and ulcerative colitis
Dermatologists — for plaque psoriasis and hidradenitis suppurativa
Ophthalmologists / uveitis specialists — for non-infectious uveitis
Nurse practitioners and physician assistants — in rheumatology, GI, and derm practices; scope of practice varies by state
Primary care providers (PCPs) — less commonly; typically defer biologic initiation to specialists for documentation and monitoring requirements
Telehealth consultation for initial evaluation is increasingly available through platforms like Teladoc and Amwell, and specialty-specific telehealth services. However, an in-person baseline evaluation (including TB testing, HBV screening, and physical exam) is almost always required before starting Hyrimoz. Follow-up visits and medication management can often be completed via video appointment after the initial workup.
No. Hyrimoz (adalimumab-adaz) is not a controlled substance and is not scheduled by the Drug Enforcement Administration (DEA). It does not have abuse potential, addiction risk, or any of the properties that lead to DEA scheduling.
However, Hyrimoz does require a valid prescription from a licensed healthcare provider. It is classified as a specialty biologic requiring prior authorization from insurance plans, monitoring for serious side effects (infections, malignancies), baseline testing (TB test, HBV screening), and dispensing through specialty pharmacies. Prescriptions for Hyrimoz can be written by any licensed physician, nurse practitioner, or physician assistant, though in practice it is primarily managed by rheumatologists, gastroenterologists, and dermatologists.
The most common side effects of Hyrimoz (occurring in more than 10% of patients in clinical trials) are:
Injection site reactions (pain, redness, itching, swelling)
Upper respiratory infections (colds, sore throat)
Sinusitis
Headache
Rash
Serious infections including tuberculosis (TB), bacterial sepsis, invasive fungal infections (histoplasmosis, aspergillosis, candidiasis), and other opportunistic infections — some fatal
Lymphoma and other malignancies, including hepatosplenic T-cell lymphoma (HSTCL) — rare but often fatal, primarily in young males with IBD also on azathioprine or 6-MP
Anaphylaxis and serious allergic reactions
Hepatitis B reactivation in chronic HBV carriers
Demyelinating disease (new or worsening MS, optic neuritis, Guillain-Barré syndrome)
Cytopenias and pancytopenia
New or worsening congestive heart failure
Lupus-like syndrome
Know what you need? Skip the search.
Hadlima (adalimumab-bwwd)
Interchangeable adalimumab biosimilar from Samsung Bioepis/Organon. Preferred by some PBMs. High-concentration, citrate-free formulations available. Similar indications and dosing to Hyrimoz.
Cyltezo (adalimumab-adbm)
Interchangeable adalimumab biosimilar from Boehringer Ingelheim. Preferred by Express Scripts (Quallent). First biosimilar to receive FDA interchangeable designation. Citrate-free formulation available.
Amjevita (adalimumab-atto)
First Humira biosimilar to launch in the U.S. (January 2023). Made by Amgen. FDA interchangeable. Available in low- and high-concentration formulations.
Enbrel (etanercept)
Another TNF inhibitor for RA, PsA, AS, and plaque psoriasis. Not approved for Crohn's or ulcerative colitis. Works via a different mechanism (fusion protein rather than monoclonal antibody).
Rinvoq (upadacitinib)
Oral JAK inhibitor approved for RA, PsA, AS, Crohn's disease, UC, and plaque psoriasis. Daily pill rather than injection. Different mechanism and safety profile from TNF inhibitors.
Prefer Hyrimoz? We can find it.
Abatacept (Orencia)
majorConcurrent use significantly increases risk of serious infections with no added benefit. Combination is not recommended in RA or any other indication.
Anakinra (Kineret)
majorCombination associated with increased serious infections and neutropenia without additional benefit. Not recommended.
Other TNF blockers (etanercept, infliximab, certolizumab, golimumab)
majorConcurrent use provides no added benefit and substantially increases risk of life-threatening infections. Not recommended.
Live vaccines (MMR, varicella, nasal flu spray, yellow fever, BCG)
majorLive vaccines are contraindicated during Hyrimoz therapy. Safety also uncertain for infants exposed in utero. Inactivated vaccines (injectable flu, Shingrix, Pneumovax, Tdap) are safe.
Other biologic DMARDs (rituximab, secukinumab, ustekinumab, tocilizumab)
moderateCombination not well-studied; generally not recommended due to additive immunosuppression and infection risk. Higher infection rate observed when TNF blocker given after rituximab.
Corticosteroids (prednisone, methylprednisolone)
moderateOften combined intentionally, particularly during induction or flares. Increases overall infection risk, especially in older patients and those with comorbidities. Close monitoring required.
Methotrexate
minorFrequently combined intentionally in RA. Methotrexate reduces anti-drug antibody formation against adalimumab, helping preserve effectiveness. Monitor for infections and hepatotoxicity with regular CBC and LFTs.
NSAIDs (ibuprofen, naproxen)
minorNo major pharmacokinetic interaction. Both can be used for symptom management. Monitor kidney function with long-term combined use.
Hyrimoz (adalimumab-adaz) represents a significant opportunity for patients with serious inflammatory diseases to access a highly effective, FDA-interchangeable biologic at lower cost than brand-name Humira. With the backing of Sandoz's global biosimilar expertise and the Sandoz One Source support program, most commercially insured patients can access Hyrimoz with minimal out-of-pocket burden.
That said, navigating the specialty pharmacy system, insurance prior authorizations, and formulary-preferred biosimilar requirements can be challenging. The key is to start the process early (at least 2-3 weeks before you need a refill), leverage Sandoz One Source for support, and understand which specialty pharmacy your insurance plan requires you to use.
When pharmacy access becomes a barrier, medfinder is here to help. medfinder calls pharmacies near you to find which ones have Hyrimoz in stock and can fill your prescription — saving you the time and frustration of making call after call. Whether you're a patient or a provider's office, medfinder helps you navigate the real-world availability challenge of specialty biologics like Hyrimoz.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini